- Immunic to Participate in Industry and Scientific Conferences in June
- Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Immunic to Participate in Investor and Scientific Conferences in May
- Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
- Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation
More ▼
Key statistics
On Wednesday, Immunic Inc (IMUX:NSQ) closed at 1.15, 21.15% above the 52 week low of 0.9451 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.14 |
---|---|
High | 1.16 |
Low | 1.11 |
Bid | 1.11 |
Offer | 1.15 |
Previous close | 1.15 |
Average volume | 430.38k |
---|---|
Shares outstanding | 90.08m |
Free float | 83.12m |
P/E (TTM) | -- |
Market cap | 103.59m USD |
EPS (TTM) | -1.84 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼